Strategic Blueprint’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$11.3M Buy
12,266
+124
+1% +$126K 0.66% 31
2025
Q4
$13M Sell
12,142
-2,083
-15% -$1.99M 0.77% 24
2025
Q3
$10.9M Sell
14,225
-110
-0.8% -$81.9K 0.47% 48
2025
Q2
$11.2M Buy
14,335
+1,485
+12% +$1.15M 0.55% 40
2025
Q1
$10.6M Buy
12,850
+1,304
+11% +$1.09M 0.58% 39
2024
Q4
$8.91M Sell
11,546
-17
-0.1% -$14.1K 0.53% 43
2024
Q3
$10.2M Sell
11,563
-463
-4% -$416K 0.64% 33
2024
Q2
$10.9M Sell
12,026
-131
-1% -$105K 0.74% 28
2024
Q1
$9.46M Sell
12,157
-43
-0.4% -$30.6K 0.67% 32
2023
Q4
$7.11M Buy
12,200
+89
+0.7% +$51.9K 0.59% 37
2023
Q3
$6.51M Sell
12,111
-271
-2% -$140K 0.6% 37
2023
Q2
$5.81M Buy
12,382
+7,103
+135% +$2.98M 0.55% 38
2023
Q1
$1.81M Buy
5,279
+576
+12% +$194K 0.19% 123
2022
Q4
$1.72M Sell
4,703
-523
-10% -$185K 0.2% 124
2022
Q3
$1.69M Buy
5,226
+53
+1% +$16.8K 0.2% 119
2022
Q2
$1.68M Buy
5,173
+625
+14% +$188K 0.21% 122
2022
Q1
$1.3M Buy
4,548
+240
+6% +$61.8K 0.15% 142
2021
Q4
$1.19M Buy
4,308
+1,312
+44% +$333K 0.15% 154
2021
Q3
$692K Buy
2,996
+131
+5% +$32.3K 0.11% 189
2021
Q2
$658K Buy
2,865
+225
+9% +$45.2K 0.1% 197
2021
Q1
$493K Sell
2,640
-245
-8% -$47.9K 0.1% 172
2020
Q4
$487K Buy
2,885
+287
+11% +$42.9K 0.12% 142
2020
Q3
$385K Buy
2,598
+545
+27% +$84.3K 0.12% 143
2020
Q2
$337K Buy
+2,053
New +$315K 0.12% 118

Other funds holding LLY

Strategic Blueprint's LLY Position: Q1 2026 in Review

Strategic Blueprint increased its Eli Lilly (LLY) stake by 1% in Q1 2026, buying an estimated $126K and bringing the position to 12,266 shares worth $11.3M. The position accounts for 0.66% of the portfolio, ranked #31.

Strategic Blueprint first reported a position in LLY in Q2 2020 and has held it in 24 quarters since. The position peaked at $13M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Strategic Blueprint held 12,266 shares of Eli Lilly worth $11.3M as of Q1 2026.
  • Strategic Blueprint bought 124 Eli Lilly shares in Q1 2026, an estimated $126K.
  • Eli Lilly made up 0.66% of Strategic Blueprint's portfolio in Q1 2026, its #31 holding.
  • Strategic Blueprint first reported a position in Eli Lilly in Q2 2020 and has held it in 24 quarters since.
  • Strategic Blueprint's Eli Lilly position peaked at $13M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Strategic Blueprint's 13F filing for Q1 2026, filed 29 Apr 2026.